Thursday, 27 March 2014

GSK receives European authorisation for once-weekly type 2 diabetes treatment, Eperzan® (albiglutide)

The European Commission has granted marketing authorisation for its once-weekly diabetes treatment, Eperzan® (albiglutide). Eperzan is indicated for the treatment of type 2 diabetes mellitus in adults (GSK)

No comments:

Post a Comment